The effect of cystic fibrosis on many organs and the frequent lung infections means that it is mostly diagnosed in childhood. Somehow, for Verônica Stasiak Bednarczuk, that diagnosis did not arrive ...

Gene editing is already being used to treat a handful of rare genetic diseases; however, most therapies involve breaking or ...

The cystic fibrosis treatment leader exceeded revenue expectations, but missed slightly on earnings per share.

The drugmaker is looking to its acute pain drug, Journavx, to drive growth beyond its established line of cystic fibrosis ...

Stuart Arbuckle, who’s been with Vertex since 2012, plans to retire from his role in July. His departure comes as Vertex ...

Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company known for its cystic fibrosis (CF) treatments, is at a critical juncture as it seeks to diversify its portfolio and maintain its ...

CRISPR & Cas Genes Market Growing funding in gene therapy worldwide is a prominent factor driving the CRISPR & Cas genes market.

Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming the healthcare ...

Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company with a market capitalization of $113.7 billion, is navigating a critical juncture as it seeks to expand its therapeutic reach and ...

Genetic diseases caused by mutations in DNA, affect millions worldwide, leading to conditions ranging from cystic fibrosis to sickle ... employs cutting-edge gene editing technologies to ...

The “dual switch selection gene drive,” an inventive technique, was described in detail in a study that was published in Nature Biotechnology. As tumors develop resistance mechanisms ...

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing ...